ALK and lung adenocarcinoma: At our institution, somatic mutation detection using immunochemistry and NGS Panel CLv3 and single tests for ROS1 and ALK mutations was performed for nearly all lung adenocarcinoma patients at the time of diagnosis, and finally, almost half of them had negative findings (42%).